{"id":44785,"date":"2022-06-07T13:01:35","date_gmt":"2022-06-07T11:01:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/"},"modified":"2022-06-07T13:01:35","modified_gmt":"2022-06-07T11:01:35","slug":"study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/","title":{"rendered":"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400"},"content":{"rendered":"
\n

\nRooms using the device showed a 52% reduced total bacterial count over a 5-day period, including a 60% reduction in opportunistic pathogens<\/i><\/b>\n<\/p>\n

<\/a>
<\/a><\/p>\n

STAMFORD, Conn.–(BUSINESS WIRE)–WellAir<\/a>, a leading provider of indoor air disinfection and purification solutions, today released real-world test results<\/a> demonstrating how its Defend 400<\/a> device reduced airborne bacteria at an urgent care outpatient facility in New Jersey. Compared to the control, the Defend 400 significantly reduced airborne bacteria in the combined four rooms by 52% and reduced opportunistic pathogens by 60% over a five-day period.\n<\/p>\n

\nThe objective of the study, run by WellAir and analyzed by EMSL Analytical Inc, was to determine whether the Defend 400 would decrease airborne bacterial counts as compared to the control (no device) in an urgent care outpatient facility occupied by doctors, nurses, staff and patients.\n<\/p>\n

\n\u201cOur Defend 400 device has been proven to minimize contaminants safely and effectively in many independent laboratory tests. The next step was to further validate those findings in a real-world setting,\u201d said Felipe Soberon, WellAir\u2019s Chief Science Officer. \u201cThis data showcases the efficacy of our solutions in healthcare environments where people are constantly coming and going. In these spaces, high-quality indoor air is critical to patient outcomes and provider protection.\u201d\n<\/p>\n

\nThe study was conducted in November 2021 inside a New Jersey urgent care outpatient facility that was running at normal capacity and actively treating patients. The testing was performed in several locations: an examination room, nurse station, break room, and waiting room within the facility. The size of the environments ranged from 96 to 896 square feet.\n<\/p>\n

\nDuring the five consecutive days, the Defend 400 significantly reduced total bacterial count by 52%, which included a 60% reduction in opportunistic pathogens and a 43% reduction in pathogenic bacteria.\n<\/p>\n

\nReduction in airborne pathogens may decrease transmission of airborne transmitted infectious diseases at healthcare institutions. In 2021 laboratory testing<\/a>, the Defend 400 demonstrated the ability to reduce the concentration of active SARS-CoV-2 from the air at an average of 49.20% reduction after 15 minutes and 99.86% after 45 minutes. A 2020 intervention study<\/a> of two ICU units using WellAir\u2019s Protect 800\/900 and Defend 1050 found that air purifiers, in addition to the hospital HVAC systems, may be an effective way to reduce the microbial load in the air and surfaces and thus hospital-acquired infections. Further studies are required to demonstrate this.\n<\/p>\n

\nThe Defend 400 is an FDA-cleared Class II medical device that combines WellAir\u2019s patented NanoStrike\u2122 Technology<\/a> with a triple-stage filtration system from Camfil\u00ae. The device complements existing infection prevention practices such as built-in heating and air conditioning systems, social distancing, hand and surface disinfection, and the use of masks.\n<\/p>\n

\nThe Defend 400 is available now. For more information on WellAir\u2019s FDA-cleared air cleaning systems, visit: wellairsolutions.com\/healthcare-portable-air-cleaners<\/a>\n<\/p>\n

\nAbout WellAir<\/b>\n<\/p>\n

\nWellAir\u2019s mission is to make the indoor world cleaner and safer. The company\u2019s broad range of clean air and surface products are scientifically proven to help safeguard how people work, live and play. WellAir, headquartered in Dublin, Ireland, with offices in Research Triangle Park, North Carolina, and Stamford, Connecticut, is a leading provider of infection control solutions.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
Cindy Caserta
\n
VP Marketing
\n
ccaserta@wellairsolutions.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Rooms using the device showed a 52% reduced total bacterial count over a 5-day period, including a 60% reduction in opportunistic pathogens STAMFORD, Conn.–(BUSINESS WIRE)–WellAir, a leading provider of indoor air disinfection and purification solutions, today released real-world test results demonstrating how its Defend 400 device reduced airborne bacteria at an urgent care outpatient facility … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44785","6":"format-standard","7":"category-industry"},"yoast_head":"\nStudy Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Rooms using the device showed a 52% reduced total bacterial count over a 5-day period, including a 60% reduction in opportunistic pathogens STAMFORD, Conn.–(BUSINESS WIRE)–WellAir, a leading provider of indoor air disinfection and purification solutions, today released real-world test results demonstrating how its Defend 400 device reduced airborne bacteria at an urgent care outpatient facility ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-07T11:01:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220607005239\/en\/1477558\/21\/WellAir_Defend_4_FDA_Cleared.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400\",\"datePublished\":\"2022-06-07T11:01:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/\"},\"wordCount\":525,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607005239\\\/en\\\/1477558\\\/21\\\/WellAir_Defend_4_FDA_Cleared.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/\",\"name\":\"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607005239\\\/en\\\/1477558\\\/21\\\/WellAir_Defend_4_FDA_Cleared.jpg\",\"datePublished\":\"2022-06-07T11:01:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607005239\\\/en\\\/1477558\\\/21\\\/WellAir_Defend_4_FDA_Cleared.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607005239\\\/en\\\/1477558\\\/21\\\/WellAir_Defend_4_FDA_Cleared.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/","og_locale":"en_US","og_type":"article","og_title":"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400 - Pharma Trend","og_description":"Rooms using the device showed a 52% reduced total bacterial count over a 5-day period, including a 60% reduction in opportunistic pathogens STAMFORD, Conn.–(BUSINESS WIRE)–WellAir, a leading provider of indoor air disinfection and purification solutions, today released real-world test results demonstrating how its Defend 400 device reduced airborne bacteria at an urgent care outpatient facility ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-07T11:01:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220607005239\/en\/1477558\/21\/WellAir_Defend_4_FDA_Cleared.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400","datePublished":"2022-06-07T11:01:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/"},"wordCount":525,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607005239\/en\/1477558\/21\/WellAir_Defend_4_FDA_Cleared.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/","url":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/","name":"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607005239\/en\/1477558\/21\/WellAir_Defend_4_FDA_Cleared.jpg","datePublished":"2022-06-07T11:01:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220607005239\/en\/1477558\/21\/WellAir_Defend_4_FDA_Cleared.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220607005239\/en\/1477558\/21\/WellAir_Defend_4_FDA_Cleared.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/study-shows-significantly-reduced-airborne-bacteria-in-urgent-care-outpatient-facility-using-wellairs-defend-400\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir\u2019s Defend 400"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44785"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44785\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}